Pfizer and Mylan, the maker of EpiPens, are merging. Pfizer will offload Upjohn, its portfolio of drugs that are no longer protected by patents, including Viagra, Lipitor and Celebrex, combining with rival Mylan to create a new company that will have a new, yet-to-be-announced name.
Since June of 2014, Alice has become one of the most feared names in patent prosecution. Rejections citing Alice have multiplied exponentially since then, and they now account for more than 60% of §101 rejections and more than 8% of all rejections, as of our latest analysis.  But Alice rejections aren’t necessarily fatal to an application – and we found the firms to prove it. Which firms are...
Back in 2016, we looked at the Fastest Growing Patent Law Firms, or as we called them, "The Rainmaker Firms." Now two years later, we want to get a fresh look at which law firms are the fastest growing in terms of patent filings with the USPTO.

The USPTO: A Snapshot

January 17, 2018
An Overview of Patent Prosecution Trends at the USPTO Since the Year 2000   Since the year 2000, there have been major shifts in law, policy, and the technological landscape that have had profound impacts on patent prosecution practice at the USPTO. Although we often focus our analytics on small corners of the USPTO, such as individual industries, art unit groups, and practice entities, we...
When we think about the technologies that have changed the face of the world and built the modern era, it is impossible to forget or ignore the role of the automotive industry. The automotive industry and the broader sector that it supports defined more than two generations of economic prosperity and mobility in the United States. The automobile in many ways marked the maturity of the...
In Part I of our Using Juristat's Examiner Reports series, we explained how understanding an examiner's key metrics can help you estimate expense, allocate resources, and manage client expectations. In this post, we'll take a closer look at responding to office actions, including interviews, appeals, and the effects of filing a continuation or continuation-in-part.  ...
Our Patent Examiner Reports give attorneys, agents, and in-house teams nearly limitless advantages over the competition. Every time you open an Examiner Report, our system performs over a billion calculations to return the most up-to-date information. As of this writing, Juristat’s database covers approximately 9,000 active examiners in almost 900 art units. Not only that, we have data on...
As part of our ongoing effort to uncover the firms that perform the best using various key metrics of skill in patent prosecution (allowance rate, speed to disposition, number of claims lost, etc.), we wanted to rank some of the most efficient law firms for patent prosecution. Now, there are several methods for measuring "efficiency" in patent prosecution, the most obvious being average speed to...
Integration will let users access examiner statistics from within their favorite management software  
As we continue to investigate major rivalries in the patent law world, we now turn our attention away from market-based competition and onto academic competition. This is a type of rivalry that, while generally good-natured, can get quite heated as various schools battle it out in academic rankings, job placement statistics, and on the field. When it comes to academic rivalries in the sector,...

Want your RFP to stand out?

Watch our webinar on using data to improve your busniess development. 

DOWNLOAD

 

See how Juristat can transform your patent practice. 

GET A DEMO